The recent French prospective ENVIE study has shed light on the protective properties of the monoclonal antibody nirsevimab (Beyfortus) in young infants against respiratory syncytial virus (RSV) related hospitalizations. This study, published in the New England Journal of Medicine, reported promising results which indicate that nirsevimab is effective in preventing RSV-associated bronchiolitis in infants under
A recent study presented at the American Society of Clinical Oncology (ASCO) meeting highlighted the potential of liposomal gemcitabine in combination with pembrolizumab for the treatment of advanced solid tumors. Dr. Charles Farber, from Atlantic Hematology Oncology, delved into the feasibility and tolerability of this innovative therapy during the conference. The use of liposomal gemcitabine